# Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

> **NCT04211922** · PHASE2 · TERMINATED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 4 (actual)

## Conditions studied

- ALK-positive Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Alkotinib Capsules

## Key facts

- **NCT ID:** NCT04211922
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-21
- **Primary completion:** 2022-10-11
- **Final completion:** 2022-10-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor R\&D Strategy Adjustment
- **Last updated:** 2024-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04211922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04211922, "Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04211922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*